Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016
September 20 2016 - 6:33AM
Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage
biotherapeutics company, today announced the planned transition of
Fabian Tenenbaum, current Chief Financial Officer and Chief
Business Officer, to Chief Executive Officer of the company,
succeeding Jonathan Peacock, who will retain his position as
Chairman of the Board and remain actively involved. The transition
will be completed by year-end.
Commenting on the management transition, Mr. Peacock noted:
“Bellerophon has made significant clinical progress of late,
most recently having dosed the first patient in its Phase 3 program
for the INOpulse® delivery system for patients with Pulmonary
Arterial Hypertension (PAH), as well as having dosed the first
patient in our Phase 2 trial in patients with pulmonary
hypertension associated with Idiopathic Pulmonary Fibrosis
(PH-IPF). In addition, plans are in place to complete further Phase
2 clinical testing for patients suffering from pulmonary
hypertension associated with chronic obstructive pulmonary disease
(PH-COPD).
“I am confident that we will have a seamless transition as
Fabian and our experienced leadership team continue to execute on
these programs. I intend to stay actively involved in the business
as Chairman and look forward to us bringing INOpulse therapies to
market for these underserved patients.”
Mr. Tenenbaum noted, “I am honored to have been chosen to
succeed Jon as CEO. I look forward to continuing to work with
our leadership team, lead investigators and other partners to
execute on our clinical trials and move the company toward
commercialization.”
About Bellerophon
Bellerophon Therapeutics is a clinical-stage
biotherapeutics company focused on developing innovative therapies
at the intersection of drugs and devices that address significant
unmet medical needs in the treatment of cardiopulmonary diseases.
The Company is currently developing three product candidates under
its INOpulse program, a proprietary pulsatile nitric oxide delivery
device. The first is for the treatment of pulmonary arterial
hypertension (PAH), for which the Company has commenced Phase 3
clinical trials in 2016. The second is for the treatment of
pulmonary hypertension associated with chronic obstructive
pulmonary disease (PH-COPD) and the third candidate is for the
treatment of pulmonary hypertension associated with Idiopathic
Pulmonary Fibrosis (PH-IPF) both of which are in Phase 2
development. The Company’s plans call for the completion of further
work on the use of INOpulse to treat PH-COPD and PH-IPF during
2016. For more information, please visit
www.bellerophon.com.
Forward-looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements about
clinical development of our product candidates and expectations
regarding the sufficiency of our cash balance to fund clinical
trials, operating expenses and capital expenditures, and other
statements containing the words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “would,” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: the uncertainties inherent in the initiation of
future clinical trials, availability and timing of data from
ongoing and future clinical trials and the results of such trials,
whether preliminary results from a clinical trial will be
predictive of the final results of that trial or whether results of
early clinical trials will be indicative of the results of later
clinical trials, expectations for regulatory approvals,
availability of funding sufficient for our foreseeable and
unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the “Risk Factors”
section of our most recent filings with the Securities and Exchange
Commission. In addition, any forward-looking statements included in
this press release represent our views only as of the date of this
release and should not be relied upon as representing our views as
of any subsequent date. We specifically disclaim any obligation to
update any forward-looking statements included in this press
release.
Contact
At Bellerophon:
Fabian Tenenbaum, Chief Financial Officer
(908) 574-4767
At Rx Communications Group:
Melody Carey
(917) 322-2571
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
From Apr 2024 to May 2024
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
From May 2023 to May 2024